A - Agilent Earnings

Archives
1

Gonna do a quick and dirty DD given what I’ve known about this company by using their products in college and making some purchasing requests as a teaching assistant for some electrical engineering classes. Actually, the relevance of my experience with these machines starts and ends with: I think they’re the most popular electrical engineering lab tech components company. That’s all as far as that goes lol.

Other things that are bullish af:

  • New board member: Dr Otis Brawley (kind of a big name in cancer research; may be interpreted as added credibility/reputation/implicit endorsement of Agilent). Announced 3 days ago.
  • Oscilloscope market is expected to generate massive revenue in the near future. See more here.
  • Agilent increased cash dividend to 21 cents per share. Announced 4 days ago.
  • USC renewed their collaboration with Agilent for another 4 years to conduct cutting edge biomolecular characterization research. Announced 3 weeks ago.
  • Global sequencing and reagents market is expected to have a compounded annual growth rate of 12.83% in the 2021-2028 period. Agilent is a leader in this segment. Report came out 3 days ago.

This is a lot of bullish news very close to Agilent’s ER. On top of that, the earnings whisper is $1.20 EPS whereas the consensus is $1.17. According to our bud Mirmir, the score for this whisper is 4, which is highly bullish iirc, but someone correct me.

image
image3035×1416 150 KB

This was a super quick and dirty DD, so please take everything with a grain of salt and please correct me on any stupid assumptions I may’ve made.

Positions:

Only playing one call: $165c 12/17

1 Like
2

Nice DD, I work with Agilent in the analytical chem space and we have a bunch of their systems. If you look at PKI (similar to Agilent, do a little more client interaction than Agilent in my experience) they did well this earnings. Looks like Brawley is a great add, has research experience through academia and seems to specialize in breast and prostate cancer. Also, with mRNA vaccines hot right now their sequencing reagents could potentially provide surprise. I won’t be playing because I jave other plays but I wouldn’t be surprised if they did well

1 Like
3

EPS reported: $1.21 (beat 3.42%)
Revenue reported: $1.66B (beat 14.48%)

Not sure why the fucken stonk is down tho.

Sources: https://s24.q4cdn.com/305549747/files/doc_financials/2021/q4/Q4’21_Results-Presentation.pdf, https://s24.q4cdn.com/305549747/files/doc_financials/2021/q4/Q4’21-Financial-Information-(Final)-v1.pdf

4

What was whisper EPS/revenue? Also how’s guidance? Could have been something in the call as well.

Sometimes everything lines up in your favor and stock still moves the other way, welcome to earnings.

5

In 2014, Keysight was spun off from Agilent Technologies, taking with it the product lines focused on electronics and radio, leaving Agilent with the chemical and bio-analytical products.

Keysight has the oscilloscope department now, not Agilent.

6

Est EPS: $1.17; Actual: $1.21
Est Rev: $1.45B; Actual: $1.66B

I read the ER and guidance seems alright? Expected Y/Y EPS and Rev growth for '22 is 5.5% and 7% respectively compared to 5.9% and 7.2% this year. This is my first earnings DD so I dunno if that guidance is considered good enough, but if I were an investor idt I’d make much of that small of a Y/Y growth rate reduction?